MXPA02007675A - Formulacion anticonceptiva masculina que comprende noretisterona. - Google Patents
Formulacion anticonceptiva masculina que comprende noretisterona.Info
- Publication number
- MXPA02007675A MXPA02007675A MXPA02007675A MXPA02007675A MXPA02007675A MX PA02007675 A MXPA02007675 A MX PA02007675A MX PA02007675 A MXPA02007675 A MX PA02007675A MX PA02007675 A MXPA02007675 A MX PA02007675A MX PA02007675 A MXPA02007675 A MX PA02007675A
- Authority
- MX
- Mexico
- Prior art keywords
- norethisterone
- testosterone
- male contraceptive
- males
- progestin
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940053934 norethindrone Drugs 0.000 title abstract 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 title abstract 3
- 239000002583 male contraceptive agent Substances 0.000 title abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- 206010003883 azoospermia Diseases 0.000 abstract 2
- 239000000583 progesterone congener Substances 0.000 abstract 2
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 abstract 1
- APTGJECXMIKIET-WOSSHHRXSA-N Norethindrone enanthate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)CCCCCC)[C@@]1(C)CC2 APTGJECXMIKIET-WOSSHHRXSA-N 0.000 abstract 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 230000001548 androgenic effect Effects 0.000 abstract 1
- 230000001076 estrogenic effect Effects 0.000 abstract 1
- 229960001652 norethindrone acetate Drugs 0.000 abstract 1
- 229960002082 norethindrone enanthate Drugs 0.000 abstract 1
- 208000008634 oligospermia Diseases 0.000 abstract 1
- 230000021595 spermatogenesis Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- -1 testosterone ester Chemical class 0.000 abstract 1
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 abstract 1
- 229960000746 testosterone undecanoate Drugs 0.000 abstract 1
- 150000003515 testosterones Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50372900A | 2000-02-15 | 2000-02-15 | |
| EP00200493 | 2000-02-15 | ||
| PCT/IB2001/000188 WO2001060376A1 (en) | 2000-02-15 | 2001-02-15 | Male contraceptive formulation comprising norethisterone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02007675A true MXPA02007675A (es) | 2004-02-26 |
Family
ID=26071832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02007675A MXPA02007675A (es) | 2000-02-15 | 2001-02-15 | Formulacion anticonceptiva masculina que comprende noretisterona. |
Country Status (26)
| Country | Link |
|---|---|
| EP (2) | EP1267885B8 (enExample) |
| JP (1) | JP2003522795A (enExample) |
| KR (1) | KR20020086905A (enExample) |
| CN (1) | CN1423560A (enExample) |
| AT (2) | ATE355844T1 (enExample) |
| AU (1) | AU2001230447A1 (enExample) |
| BG (1) | BG107066A (enExample) |
| BR (1) | BR0108411A (enExample) |
| CA (1) | CA2398063A1 (enExample) |
| CY (1) | CY1106639T1 (enExample) |
| CZ (1) | CZ20022691A3 (enExample) |
| DE (2) | DE60127103T2 (enExample) |
| DK (1) | DK1267885T3 (enExample) |
| EE (1) | EE200200454A (enExample) |
| ES (1) | ES2282230T3 (enExample) |
| HK (1) | HK1049442B (enExample) |
| HU (1) | HUP0300128A3 (enExample) |
| IL (1) | IL151219A0 (enExample) |
| MX (1) | MXPA02007675A (enExample) |
| NO (1) | NO20023607L (enExample) |
| PL (1) | PL357185A1 (enExample) |
| PT (1) | PT1267885E (enExample) |
| RU (1) | RU2002124602A (enExample) |
| SI (1) | SI1267885T1 (enExample) |
| SK (1) | SK11602002A3 (enExample) |
| WO (1) | WO2001060376A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10234525A1 (de) * | 2002-07-25 | 2004-02-05 | Schering Ag | Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung |
| TW200404552A (en) * | 2002-05-30 | 2004-04-01 | Akzo Nobel Nv | Self administered contraception |
| EA008147B1 (ru) | 2002-07-24 | 2007-04-27 | Шеринг Акциенгезельшафт | МИКРОБИОЛОГИЧЕСКИЕ СПОСОБЫ ПОЛУЧЕНИЯ 7α-ЗАМЕЩЁННЫХ 11α-ГИДРОКСИСТЕРОИДОВ |
| CA2493207A1 (en) * | 2002-07-25 | 2004-02-05 | Schering Aktiengesellschaft | Composition containing an androgenous 11.beta.-halogen steroid and a progestational hormone, and male contraceptive based on said composition |
| JO2505B1 (en) * | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
| CN101352443B (zh) * | 2007-07-23 | 2011-01-12 | 中国科学院动物研究所 | 哺乳动物雄性不育剂 |
| EP3750538B1 (en) | 2018-03-23 | 2024-08-14 | Pharmajor International | Non-hormonal methods for male contraception comprising (r)-silodosin |
| KR20250142811A (ko) * | 2024-03-22 | 2025-09-30 | 주식회사 에아스텍 | 노르에티스테론 에난테이트 화합물의 암의 예방 또는 치료 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714420A1 (de) * | 1976-06-01 | 1977-12-08 | Int Pregnancy Advisory Service | Antikonzeptionsmittel zur verabreichung an mann und frau in einer gemeinsamen verabreichungspackung |
| US4210644A (en) | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
| US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
| CN1102095A (zh) * | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| DE19650352A1 (de) * | 1996-12-04 | 1998-07-30 | Jenapharm Gmbh | Oral wirksames Kombinationspräparat zur Kontrazeption für den Mann |
-
2001
- 2001-02-15 HK HK03101578.5A patent/HK1049442B/en not_active IP Right Cessation
- 2001-02-15 AT AT01902590T patent/ATE355844T1/de active
- 2001-02-15 DK DK01902590T patent/DK1267885T3/da active
- 2001-02-15 WO PCT/IB2001/000188 patent/WO2001060376A1/en not_active Ceased
- 2001-02-15 IL IL15121901A patent/IL151219A0/xx unknown
- 2001-02-15 PL PL01357185A patent/PL357185A1/xx not_active Application Discontinuation
- 2001-02-15 DE DE60127103T patent/DE60127103T2/de not_active Expired - Lifetime
- 2001-02-15 CA CA002398063A patent/CA2398063A1/en not_active Abandoned
- 2001-02-15 RU RU2002124602/15A patent/RU2002124602A/ru not_active Application Discontinuation
- 2001-02-15 BR BR0108411-9A patent/BR0108411A/pt not_active IP Right Cessation
- 2001-02-15 AT AT06075322T patent/ATE474580T1/de not_active IP Right Cessation
- 2001-02-15 CZ CZ20022691A patent/CZ20022691A3/cs unknown
- 2001-02-15 SK SK1160-2002A patent/SK11602002A3/sk unknown
- 2001-02-15 KR KR1020027010715A patent/KR20020086905A/ko not_active Withdrawn
- 2001-02-15 AU AU2001230447A patent/AU2001230447A1/en not_active Abandoned
- 2001-02-15 EE EEP200200454A patent/EE200200454A/xx unknown
- 2001-02-15 CN CN01808041A patent/CN1423560A/zh active Pending
- 2001-02-15 EP EP01902590A patent/EP1267885B8/en not_active Expired - Lifetime
- 2001-02-15 DE DE60142647T patent/DE60142647D1/de not_active Expired - Lifetime
- 2001-02-15 EP EP06075322A patent/EP1666044B1/en not_active Expired - Lifetime
- 2001-02-15 ES ES01902590T patent/ES2282230T3/es not_active Expired - Lifetime
- 2001-02-15 MX MXPA02007675A patent/MXPA02007675A/es unknown
- 2001-02-15 SI SI200130726T patent/SI1267885T1/sl unknown
- 2001-02-15 HU HU0300128A patent/HUP0300128A3/hu unknown
- 2001-02-15 JP JP2001559472A patent/JP2003522795A/ja active Pending
- 2001-02-15 PT PT01902590T patent/PT1267885E/pt unknown
-
2002
- 2002-07-30 NO NO20023607A patent/NO20023607L/no not_active Application Discontinuation
- 2002-09-05 BG BG107066A patent/BG107066A/xx unknown
-
2007
- 2007-06-05 CY CY20071100743T patent/CY1106639T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106639T1 (el) | Τυποποιηση αντισυλληπτικου για ανδρες που περιλαμβανει νορεθιστερονη | |
| NO20032805D0 (no) | Preparater av östrogensyklodekstrinkomplekser | |
| GEP20053586B (en) | Selective Androgen Receptor Modulators and Pharmaceutical Compositions Containing the Same | |
| KR960704553A (ko) | 적어도 하나의 프로게스토겐과 적어도 하나의 에스트로겐을 함유하는 대용요법용 제제(preparation for substitution therapy containing at least one progestogen and at least one estrogen) | |
| WO2001003687A3 (en) | Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans | |
| AR073972A2 (es) | Composiciones farmaceuticas para el tratamiento de carencias estrogenicas en la menopausia y para la prevencion de la osteoporosis en mujeres menopausicas | |
| DE122007000011I1 (de) | Feste Arzneiformen, enthaltend Clathrate vom steroidalen Sexualhormon Ethinylestradiol | |
| RU99118582A (ru) | Композиция для чрескожного введения стероидных лекарственных средств | |
| CA2467237A1 (en) | Method of preventing or treating benign gynaecological disorders | |
| HUP0200173A2 (en) | Combined use of estrogen and progestogen, norethindrone acetate and ethinyl estradiol for preparing pharmaceutical compositions for preventing and treating skin aging and acne | |
| DE59805902D1 (de) | Nichtestrogene derivate des estradiols mit antioxidativer aktivität | |
| WO2001040255A3 (en) | 14,15-beta-methylene substituted androgens | |
| AU1967300A (en) | Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11 | |
| WO2004091535A3 (en) | Methods of administering estrogens and progestins | |
| CO5580789A2 (es) | Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis | |
| JP2003522795A5 (enExample) | ||
| AR027526A1 (es) | Formulacion anticonceptiva masculina que comprende noretisterona | |
| PE20010579A1 (es) | Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos | |
| JP2005532336A (ja) | 新規なエトノゲストレルエステルの使用 | |
| PL1635843T3 (pl) | Hormonalna terapia zastępcza i leczenie depresji obejmujące dienogest | |
| YU16403A (sh) | 4-halogenovani 17-metilen steroidi, postupak njihove proizvodnje i farmaceutski sastavi koji sadrže ova jedinjenja | |
| ECSP10010152A (es) | Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa |